Morgan Stanley researchers have set the price target for shares of Boston Scientific at $20, according to a Mideast Times report.
Morgan Stanley has a “buy” rating on the stock. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.84, according to the report.
More articles on gastroenterology:
Check-Cap IPO unites to trade separately from March 18 onwards
Akron General Partners Physician Group adds Dr. Jeffery Neher
Actavis completes $70.5B Allergan acquisition
Gastroenterologists are facing increasing financial strain as reimbursement rates continue to decline. A study published in The American Journal of…
Law firm Edelson Lechtzin is investigating privacy violations at Gastroenterology Associates of Central Florida, also known as the Center for…
A case in front of the U.S. Supreme Court could limit the U.S. Preventive Services Task Force's role in preventive…